NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $61.63 -8.48 (-12.10%) Closing price 04:00 PM EasternExtended Trading$61.52 -0.12 (-0.19%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About 10x Genomics Stock (NASDAQ:TXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get 10x Genomics alerts:Sign Up Key Stats Today's Range$61.24▼$71.0050-Day Range$59.98▼$97.7452-Week Range$12.80▼$102.81Volume5.17 million shsAverage Volume3.02 million shsMarket Capitalization$8.03 billionP/E RatioN/ADividend YieldN/APrice Target$68.00Consensus RatingHold Company Overview 10x Genomics, Inc. is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods. The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples. These platforms are supported by specialized instruments, consumables, reagents and software used in applications such as biomedical research, drug discovery, immunology, neuroscience and cancer research. Founded in 2012, 10x Genomics is headquartered in Pleasanton, California, and serves academic, pharmaceutical, biotechnology and other research organizations internationally. The company was co-founded by Serge Saxonov, who serves as its chief executive officer.AI Generated. May Contain Errors. Read More 10x Genomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreTXG MarketRank™: 3.007170795305 of 5 stars10x Genomics scored higher than 60% of companies evaluated by MarketBeat, and ranked 647th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingHold Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on no strong buy ratings, 5 buy ratings, 12 hold ratings, and 1 sell rating.Upside Potential10x Genomics has a consensus price target of $68.00, representing about 10.3% upside from its current price of $61.63.Amount of Analyst Coverage10x Genomics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($0.77) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -104.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -104.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 9.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about 10x Genomics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.72% of the float of 10x Genomics has been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 2.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 10x Genomics has recently decreased by 17.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.64 News Sentiment10x Genomics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for 10x Genomics this week, compared to 6 articles on an average week.Search Interest18 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows13 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,810,070.00 in company stock.Percentage Held by Insiders8.84% of the stock of 10x Genomics is held by insiders.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TXG Stock News Headlines10x Genomics Appoints Two New Directors to Board43 minutes ago | tipranks.com10x Genomics Sinks 12%, Twist Down 15%, PacBio Down 10% as Genomics Stocks Give Back Rebound1 hour ago | finance.yahoo.comDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start with $150,000 and it's gone in under six years. A new Prudential survey of more than 3,000 Americans over 50 found 86% don't feel free to spend their savings on things they enjoy. Tim Plaehn, who has advised investors since the 1980s, is tracking a monthly income fund built on major U.S. companies that pays cash without requiring investors to sell shares.November 2 at 1:00 AM | Investors Alley (Ad)10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium AnalysisNovember 2 at 9:00 AM | prnewswire.comWill TXG Stock Ever Get Back To Its Old High?October 30 at 4:27 PM | finance.yahoo.com10x Genomics: Atera Takes Off, But Valuation Flies Too HighOctober 28, 2026 | seekingalpha.com10x Genomics (TXG) Stock Looks Expensive On Its 485% One Year RunOctober 28, 2026 | finance.yahoo.com10x Genomics (NASDAQ:TXG) Shares Cross Above Fifty Day Moving Average Following Analyst DowngradeOctober 28, 2026 | americanbankingnews.comSee More Headlines TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $16.31 at the start of the year. Since then, TXG stock has increased by 277.9% and is now trading at $61.63. How were 10x Genomics' earnings last quarter? 10x Genomics (NASDAQ:TXG) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.10. The company's quarterly revenue was down 12.7% compared to the same quarter last year. Read the conference call transcript. When did 10x Genomics IPO? 10x Genomics (TXG) raised $370 million in an IPO on Thursday, September 12th 2019. The company issued 10,000,000 shares at a price of $36.00-$38.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? 10x Genomics' top institutional investors include Sumitomo Mitsui Trust Group Inc. (1.73%), Counterpoint Mutual Funds LLC (0.10%), Simplify Asset Management Inc. and Maxi Investments CY Ltd (0.05%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Justin J Mcanear, James Wilbur, Alan Mateo and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 10x Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include NVIDIA (NVDA), Tesla (TSLA), CRISPR Therapeutics (CRSP), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Block (XYZ). Company Calendar Last Earnings8/06/2026Today11/02/2026Next Earnings (Estimated)11/05/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TXG's financial health is in the Green zone, according to TradeSmith. TXG has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:TXG CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,178Year Founded2012Price Target and Rating Average Price Target for 10x Genomics$68.00 High Price Target$110.00 Low Price Target$17.00 Potential Upside/Downside+10.3%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.54 million Net Margins-12.18% Pretax Margin-12.14% Return on Equity-9.33% Return on Assets-7.30% Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.25 Sales & Book Value Annual Sales$642.82 million Price / Sales12.49 Cash FlowN/A Price / Cash FlowN/A Book Value$6.24 per share Price / Book9.88Miscellaneous Outstanding Shares130,290,000Free Float118,773,000Market Cap$8.03 billion OptionableOptionable Beta2.03 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:TXG) was last updated on 11/2/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredTesla pays $0 in dividends. This new fund paid $452 in one month on $5,000.Tesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a differen...Investors Alley | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredDollar Reset – Are You Prepared?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
